[1] 李艳丽,廖勇敢,李晓雯,等.糖尿病肾病发病的危险因素分析[J].实用预防医学,2017,24(2):133-136. [2] 王洁,何媛,于珮,等.糖尿病肾病的相关危险因素分析[J].国际内分泌代谢杂志,2015,35(3):153-157. [3] Shaheer AK,Tharayil JK,Krishna PW.A Comparative study of high sensitivity C-reactive protein and metabolic variables in type 2 diabetes mellitus with and without nephropathy[J].J Clin Diagn Res,2017,11(9):BC01-BC04. [4] 赵昔良,叶益聪,张抒扬,等.美国糖尿病学会新版糖尿病诊断标准对择期冠状动脉造影患者糖代谢异常的筛查意义[J].中华内科杂志,2015,54(4):302-306. [5] 黄炎,章爽,黄伟,等.肾损伤分子-1在糖尿病肾脏早期损伤中的诊断价值研究[J].中国实验诊断学,2017,21(8):1299-1302. [6] 袁国忠,吴建军,黄勇坚,等.尿微量清蛋白和尿N-乙酰-β-D氨基葡萄糖苷酶对糖尿病肾病的诊断意义[J].国际检验医学杂志,2017,38(10):1410-1411. [7] 罗娅,郑国波,杨雪峰,等.2型糖尿病患者血清中壬基酚负荷的检测及分析[J].实用医学杂志,2016,32(13):2227-2230. [8] 热孜万古力·阿帕尔,吴红.2型糖尿病肾病患者检测血清基质金属蛋白酶-10的意义[J].现代检验医学杂志,2016,31(3):111-113. [9] 周娲,胡文杰,李培芳,等.糖尿病肾病肾功能衰竭患者血清胆红素与左室舒张功能的关系[J].广东医学,2017,38(1):115-117. [10] Lee YH,Kim KP,Kim YG,et al.Clinicopathological features of diabetic and nondiabetic renal diseases in type 2 diabetic patients with nephrotic-range proteinuria[J].Medicine (Baltimore),2017,96(36):e8047. [11] Joly D,Choukroun G,Combe C,et al.Glycemic control according to glomerular filtration rate in patients with type 2 diabetes and overt nephropathy: a prospective observational study[J].Diabetes Res Clin Pract,2015,108(1):120-127. [12] 马海建,巫冠中.糖尿病肾病发病分子机制[J].现代生物医学进展,2014,14(16):3184-3187. [13] Miao J,Friedman E,Wu AHB,et al.Clinical utility of single molecule counting technology for quantification of KIM-1 in patients with heart failure and chronic kidney disease[J].Clin Biochem,2017,50(16-17):889-895. [14] 林永梅,陈映,陈姮熹,等.Kim-1、PAI-1及Hsp72联合检测对糖尿病早期肾损害的诊断价值[J].西南国防医药,2017,27(3):247-250. [15] 刘培培,马飞,李兴翠,等.尿N乙酰-β-D氨基葡萄糖苷酶、β2微球蛋白对2至4期慢性肾病患者的临床意义[J].标记免疫分析与临床,2015,22(4):262-264. [16] 刘品力,陈燕玲.ACE及AGT基因多态性与糖尿病肾病发病风险的关系[J].中国老年学杂志,2015,27(15):4177-4179.
2018, Vol. 25 
